1. National Institute for Health and Care Excellence . Crohn's disease management in adults, children and young people. Clinical guideline 152. London: NICE, 2012. www.nice.org.uk/guidance/cg152/evidence/full-guideline-pdf-8950812381 [Accessed 2 February 2018].
2. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial
3. National Institute for Health and Care Excellence . Infliximab and adalimumab for the treatment of Crohn's disease. Technology appraisal 187. London: NICE 2010. www.nice.org.uk/guidance/ta187 [Accessed 5 February 2018].
4. National Institute for Health and Care Excellence . Ustekinumab for moderately to severely active Crohn's disease after previous treatment. Technology appraisal guidance 456. London: NICE, 2017. www.nice.org.uk/guidance/ta456 [Accessed 5 February 2018].
5. National Institute for Health and Care Excellence . Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy. Technology appraisal guidance 352. London: NICE, 2015. www.nice.org.uk/guidance/ta352 [Accessed 5 February 2018].